Categories
Change Password!
Reset Password!
Preoperative TAP block with liposomal bupivacaine provides a significant reduction in the opioid intake in patients undergoing bariatric procedure.
According to a retrospective chart review published in the Journal of Obesity Surgery, preoperative TAP block with liposomal bupivacaine provides significant outcomes in reducing the opioid consumption among people suffering from the post-operative pain after inpatient and outpatient surgeries.
A total of 191 participants who went through a
laparoscopic bariatric procedure from 13 September 2017 to 26
February 2018 were selected for the analysis. 97 out of 191 obtained
TAP block with liposomal bupivacaine and others did not obtain TAP
block. Both groups showed comparable baseline patient
characteristics. The mean preoperative body mass index (BMI) of TAP
and non-TAP groups noticed was 45.6 and 46.1 kg/m2,
respectively. The mean age of the patients of TAP and non-TAP groups
measured was 43.7 and 41.1 years, respectively. As compared to the 93
patients of the non-TAP group, 65 patients of TAP group received
intravenous (IV) morphine or hydromorphone. The number of patients
taken oral opioid analgesics of TAP and non-TAP groups noticed was 44
and 73, respectively. The odds of taking IV morphine or hydromorphone
and oral opioid analgesic for TAP group was around 0.10 times and
0.29 times the corresponding odds for the non-TAP group,
respectively.
The preoperative TAP block with liposomal bupivacaine
significantly reduces the IV opioid intake. However, a larger
prospective study is required to validate the results further.
Obesity Surgery
Preoperative Transversus Abdominis Plane (TAP) Block with Liposomal Bupivacaine for Bariatric Patients to Reduce the Use of Opioid Analgesics.
Rena C. Moon et al.
Comments (0)